Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The pressure is on for Big Pharma...& Onc.

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Dec 04, 2022 7:39am

227 Views

Post# 35149239

RE:RE:RE:RE:The pressure is on for Big Pharma...& Onc.

Now that I have been thinking about it.

China's CDE (Center for Drug Evaluation) might be another avenue to explore. Tecentriq is approved in China for SCLC. After the posters on Tuesday, they might be able to apply for breakthrough therapy in China for both mBC & PDAC.

Yes, idle Sunday morning speculation, but the mind boggles when one thinks about the potential market.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand